Bruce Booth, a partner at Atlas Venture, shares expert insights on biotech trends and innovation. He discusses his annual review report, emphasizing how China's growing influence shapes the industry. The potential implications of a new FDA commissioner under a Trump administration are explored, highlighting challenges in drug approvals. Booth also reflects on investor sentiment amid political changes and the evolving landscape of pharmaceutical leadership, making predictions for the future of biotech and healthcare.

Megan Molteni discusses the history and future of CRISPR-based medicine and the expected FDA approval of the first CRISPR-based medicine. Bruce Booth joins to discuss the challenges faced by the biotech industry and prospects for optimism in 2024.